$1.42
-0.04 (-2.41%)
Open$1.47
Previous Close$1.46
Day High$1.50
Day Low$1.41
52W High$3.54
52W Low$0.76
Volume—
Avg Volume247.6K
Market Cap92.58M
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+1,798.6% upside
Current
$1.42
$1.42
Target
$26.96
$26.96
$18.17
$26.96 avg
$35.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 68.45M | 35.55M | 33.75M |
| Net Income | -13,439,175 | 3.58M | 3.41M |
| Profit Margin | -19.6% | 10.1% | 10.1% |
| EBITDA | -14,905,588 | 5.92M | 5.34M |
| Free Cash Flow | — | 3.84M | 3.54M |
| Rev Growth | — | -9.4% | +19.8% |
| Debt/Equity | — | 0.12 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |